Co-Authors
This is a "connection" page, showing publications co-authored by KEN HE YOUNG and CHI YOUNG OK.
Connection Strength
4.409
-
Checkpoint inhibitors in hematological malignancies. J Hematol Oncol. 2017 05 08; 10(1):103.
Score: 0.618
-
Targeting the programmed death-1 pathway in lymphoid neoplasms. Cancer Treat Rev. 2017 Mar; 54:99-109.
Score: 0.608
-
Age cutoff in lymphoma diagnosis. Aging (Albany NY). 2015 Jul; 7(7):451-2.
Score: 0.543
-
EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med. 2015 Jan 23; 47:e132.
Score: 0.527
-
EBV-positive diffuse large B-cell lymphoma of the elderly. Blood. 2013 Jul 18; 122(3):328-40.
Score: 0.468
-
Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features. Am J Surg Pathol. 2023 08 01; 47(8):849-858.
Score: 0.235
-
EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Mod Pathol. 2021 12; 34(12):2183-2191.
Score: 0.207
-
Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases. Am J Surg Pathol. 2019 10; 43(10):1421-1428.
Score: 0.182
-
Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol. 2015 Sep; 28(9):1202-13.
Score: 0.136
-
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? Oncotarget. 2015 Jun 10; 6(16):13933-45.
Score: 0.135
-
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015 May 08; 8:45.
Score: 0.134
-
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015 Mar; 39(3):348-54.
Score: 0.131
-
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res. 2014 Oct 01; 20(19):5113-23.
Score: 0.128
-
Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014 Jun 15; 120(12):1818-29.
Score: 0.124
-
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res. 2014 May 01; 20(9):2338-49.
Score: 0.124
-
NF-?B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol. 2017 06; 30(6):854-876.
Score: 0.038
-
Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of ?d T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With a? T-Cell Large Granular Lymphocytic Leukemia. [corrected]. Am J Clin Pathol. 2015 Oct; 144(4):607-19.
Score: 0.035
-
Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 2015 Sep 15; 6(27):23157-80.
Score: 0.034